BCRX Q4 2018 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-29.8% YoY

Gross Profit

$3M97.4% margin

Operating Income

-$25M-925.7% margin

Net Income

-$27M-1005.2% margin

EPS (Diluted)

$-0.25

QoQ Revenue Growth

+87.7%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$24M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$147M

Total Liabilities

$98M

Stockholders' Equity

$49M

Cash & Equivalents

$27M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$4M	-29.8%
Gross Profit	$3M	$4M	-29.3%
Operating Income	-$25M	-$18M	-41.4%
Net Income	-$27M	-$20M	-40.4%

Revenue Segments

Royalty

$2M65%

Collaborative and Other Research and Development

$954,00035%